FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis

Sanofi’s drug candidate for multiple sclerosis (MS) and myasthenia gravis (MG), tolebrutinib, has been placed on partial clinical hold by the U.S. Food and Drug Administration, with participants who have been treated for fewer than 60 days being told to stop.